Attempt to prevent hepatitis by using specific anti-HBs immunoglobulin

Area of Science:

• Hepatology
• Immunology
• Infectious Diseases

Background:

• Hepatitis B virus (HBV) poses a significant public health risk, particularly following blood exposure or in healthcare settings.
• The development of specific immunoglobulins offers a potential prophylactic measure against HBV infection.

Purpose of the Study:

• To evaluate the efficacy of specific anti-hepatitis B immunoglobulin in preventing hepatitis B infection across different exposure scenarios.
• To determine optimal dosing and administration strategies for anti-hepatitis B immunoglobulin prophylaxis.

Main Methods:

• Preparation and administration of specific anti-hepatitis B immunoglobulin batches.
• Clinical trials involving patients exposed to HBsAg-positive blood transfusions.
• Prophylaxis in accidentally contaminated laboratory and hospital personnel.
• Long-term administration in hemodialysis unit staff.

Main Results:

• A higher dose (0.5 ml/kg) of anti-hepatitis B immunoglobulin prevented hepatitis B in transfusion-exposed patients, unlike a lower dose (0.16 ml/kg).
• Prophylaxis with 0.08 ml/kg in over 1000 healthcare workers showed excellent protection against accidental exposure.
• Repeated administration in hemodialysis staff reduced clinical hepatitis B attack rates from 44% to 0%, with no cases observed in 90 protected individuals.

Conclusions:

• Specific anti-hepatitis B immunoglobulin is a highly effective prophylactic agent against hepatitis B virus infection.
• Dosing and administration schedules should be tailored to the risk of exposure for optimal prevention.
• Immunoprophylaxis with anti-hepatitis B immunoglobulin significantly reduces hepatitis B incidence in high-risk populations.